Prime Studies Reveal Efficacy, Costs of Specialty Agents
Two recently published studies by Prime Therapeutics LLC shine a light on specialty drug costs. In the first, researchers found that a newer agent for cystic fibrosis is effective, but it is so costly that its related savings in health care services avoided do not offset its cost. The second study showed that a focused communication effort for a transition to a preferred infliximab biosimilar, among other strategies, has resulted in millions of dollars in savings in only the first three months after implementation of the strategy.
Posters on the studies were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting.
Biosimilars Are Picking Up Market Share, but Some Uncertainties Still ExistREAD MORE
Researchers Examine CF, UC/Crohn’s Adherence, Say Specialty Pharmacies ‘Could Help Reduce Medical Burden’READ MORE